Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3256905 | 1.00 | KMT2A (0.50) | KMT2ASMN1; SMN2NPSR1TDP1ALDH1A1 | |
| SCHEMBL3258108 | 0.76 | HTT (0.49) | KMT2ASMN1; SMN2NPSR1TDP1ALDH1A1 | |
| SCHEMBL3256203 | 0.76 | HTR3A (0.41) | KMT2ANPSR1TDP1ALDH1A1MEN1 | |
| SCHEMBL3256205 | 0.76 | HTR3A (0.41) | KMT2ANPSR1TDP1ALDH1A1MEN1 | |
| SCHEMBL3258110 | 0.76 | HTT (0.49) | KMT2ASMN1; SMN2NPSR1TDP1ALDH1A1 | |
| SCHEMBL3259222 | 0.75 | MEN1 (0.47) | KMT2ASMN1; SMN2TDP1ALDH1A1MEN1 | |
| SCHEMBL3258947 | 0.75 | MEN1 (0.47) | KMT2ASMN1; SMN2TDP1ALDH1A1MEN1 | |
| SCHEMBL3255375 | 0.74 | P2RX7 (0.53) | SMN1; SMN2NPSR1ALDH1A1NPC1CYP3A4 | |
| SCHEMBL3255381 | 0.74 | P2RX7 (0.53) | SMN1; SMN2NPSR1ALDH1A1NPC1CYP3A4 | |
| SCHEMBL10350394 | 0.74 | NPSR1 (0.50) | KMT2ASMN1; SMN2NPSR1TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741493-B2 | 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives; antiinflammatory agent, neurodegenerative diseases; inflammatory bowel disease, rheumatoid arthritis and diseases associated with central nervous system, such as Alzheimer's disease | AVENTIS PHARMACEUTICALS INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1651613-B1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMA INC (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20080132550-A1 | HETEROCYCLIC COMPOUNDS AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-7326792-B2 | Heterocyclic compounds as P2X7 ion channel blockers | AVENTIS PHARMACEUTICALS INC. (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1651613-A1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | Aventis Pharmaceuticals, Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005014555-A1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132550-A1 | HETEROCYCLIC COMPOUNDS AS P2X7 ION CHANNEL BLOCKERS | P2RX3, P2RX2, P2RX5 | KMT2A 3229/4885SMN1; SMN2 3060/4885NPSR1 386/4885 |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | P2RX3, P2RX2, P2RX5 | KMT2A 3229/4885SMN1; SMN2 3060/4885NPSR1 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.